ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck to pay Gilead’s lawyer fees

by Marc S. Reisch
July 24, 2017 | APPEARED IN VOLUME 95, ISSUE 30

A California federal judge has ordered Merck & Co. to pay Gilead Sciences $14 million in attorney fees in a case involving Gilead’s Sovaldi and Harvoni hepatitis C virus treatments. In June 2016, the judge overturned a $200 million jury award Merck had won in a patent infringement dispute involving sofosbuvir, an active ingredient in both drugs, after she determined Merck had lied. In December 2016, Merck won a $2.5 billion jury award from Gilead in a separate patent dispute involving the hepatitis C drugs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment